Corvus Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Corvus Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $333,654 2 trades by 2 insiders 3 months later: median +16.9% (+12.9% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Corvus Pharmaceuticals, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Corvus Pharmaceuticals, Inc.’s insiders pay?

From May 16, 2016 to June 15, 2026, 11 insiders reported 54 open-market purchases and 7 sales not made under a pre-set plan in Corvus Pharmaceuticals, Inc. Twelve months after each purchase was reported, the shares were −40.5% against the S&P 500 on average (median −39.6%), over 25 purchases with a full year of prices; 4% beat the index. After sales, the shares moved −73.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 17, 2016 into $2,047 by November 2, 2026, −14.1% a year. It held shares 44% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,340 (+7.0% a year), and held throughout $43,687 (+15.2%).

Copying Corvus Pharmaceuticals, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Corvus Pharmaceuticals, Inc.'s insiders from May 17, 2016, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 44% of the time.

Corvus Pharmaceuticals, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Miller Richard A Md	President and CEO	22	−37.1% (5)	20%	0	—	May 20, 2026
Thompson Peter A.	Director	10	−40.6% (8)	0%	2	−73.8% (1)	July 1, 2025
Orbimed Advisors LLC	Director	7	−43.0% (6)	0%	1	—	July 1, 2025
Novo Holdings A/s	10% owner	3	−37.4% (3)	0%	2	—	July 9, 2020
Lea Leiv	Chief Financial Officer	4	—	—	0	—	December 15, 2022
Orbimed Capital Gp V LLC	Director	3	−33.5% (2)	0%	1	−73.8% (1)	September 22, 2021
Jones William Benton	See Remarks	2	—	—	0	—	May 7, 2024
Ecor1 Capital, LLC	10% owner	0	—	—	1	—	October 1, 2021
Gould Terry P	Director	1	−64.9% (1)	0%	0	—	March 13, 2018
Grais Linda	Director	1	—	—	0	—	May 16, 2023
Moore David Scott	Director	1	—	—	0	—	June 15, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Corvus Pharmaceuticals, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Corvus Pharmaceuticals, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −20.3% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
June 30, 2026	2 buying	−23.9%	not yet	not yet
March 29, 2018	6 buying	−6.6%	−34.5%	−76.0%
June 30, 2017	2 buying	+27.3%	−25.9%	−27.0%
May 31, 2016	4 buying	−4.4%	−0.5%	−45.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Corvus Pharmaceuticals, Inc. · Funds · Politicians